Physician profile
Sharon Nancy Farber
NPI 1083642474
$14,925.12
in general payments reported to CMS, 2019-2025
56 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,093 · 2020: $1,655 · 2021: $3,298 · 2022: $3,280 · 2023: $2,866 · 2024: $580 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,619.62 | 2019-2025 | |
| Biogen, INC. | $1,184.74 | 2019-2024 | Tysabri, Vumerity, Skyclarys |
| Ucb, INC. | $890.10 | 2019-2023 | Briviact |
| Allergan, INC. | $749.43 | 2019-2021 | |
| Amgen INC. | $638.14 | 2019-2024 | Uplizna, Aimovig |
| Biohaven Pharmaceuticals, INC. | $617.95 | 2020-2021 | |
| Emd Serono, INC. | $584.07 | 2019-2023 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $574.36 | 2019-2023 | |
| Genzyme Corporation | $501.36 | 2019-2023 | |
| Acadia Pharmaceuticals INC | $473.39 | 2019-2023 | Nuplazid |
| Lilly USA, LLC | $461.47 | 2019-2024 | Amyvid, Emgality, Reyvow |
| Celgene Corporation | $426.60 | 2021-2023 | Zeposia |
| Eisai INC. | $423.31 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $414.56 | 2021-2024 | Ingrezza, Ongentys |
| Neurelis, INC. | $362.19 | 2020-2025 | Valtoco |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Farber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.